JPRN-UMIN000019093招募中2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14) - Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 个研究点目标入组 50 人开始时间: 2015年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 20years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Cases where impaired liver, kidney and cardiac functions compromise experimental treatment (2) Patients who have been treated with anticancer drugs or radiation therapy (3) Presence of CNS degenerative lesion (4) Associated intracranial hemorrhage which hinders execution of treatment process (5) Associated infection which is difficult to control (6) Pregnant or possibility of pregnancy (7) Women who are breastfeeding (8) Past history of malignant neoplasm or multiple primary neoplasms (9) History of congenital or acquired immune deficiency syndrome (10) Any other reasons that the attending physician has deemed unsuitable
研究者
相似试验
进行中（未招募）
2 期
Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)JPRN-jRCTs041180174Koga Yuhki50
招募中
不适用
Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 TherapyMetastatic MelanomaNCT03888950Centre Hospitalier Universitaire de Nice20
招募中
不适用
Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)Metastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12612000052831Chang Gung Memorial Hospital30
已完成
2 期
A clinical trial to see whether outcomes in Hodgkins Lymphoma can be improved by using increased intensity therapy in interim PET scan positive patientsCTRI/2012/06/002741Cancer Institute50
进行中（未招募）
1 期
Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II studyAdvanced stage Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10020206Term: Hodgkin's diseaseSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10020243Term: Hodgkin's disease NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000498-35-PLEuropean Organisation for Research and Treatment of Cancer (EORTC)150